Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus taxane first-line treatment for locally recurrent or metastatic breast cancer
2006-002529-21Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of bevacizumab in breast cancer, sponsored by Roche. Primary endpoints: Incidence of bevacizumab-related serious adverse events and Incidence of specific adverse events. Started Jun 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-002529-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002529-21.